Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants.
Cholinesterases are efficient scavengers of organophosphates and are currently being developed as drugs for treatment against poisoning by such compounds. Recombinant ChE bioscavengers have very short circular longevity, a limitation that can be overcome by complex post-translation manipulations or by chemical modification such as polyethylene glycol conjugation. Series of multiple Lys-Ala mutants of human acetylcholinesterase were prepared allowing the generation of homogenous and well defined polyethylene-glycol conjugated AChEs with either one, two, three, four, or five appended polyethylene glycol (PEG) moieties/molecule. The rank order of circulatory longevity of these molecules was dependent on the number of PEG appendages up to a certain threshold: 5 = 4 > 3 > 2 > 1 > 0. Hypolysine acetylcholinesterases (AChEs) carrying the same number of PEGs, and therefore with identical masses, allowed us to demonstrate that circulatory longevity correlates with the predicted extent of concealment of the AChE surface. Furthermore, circulatory profiles of high number and low number PEG-AChEs differing in their sialic acid contents demonstrate a direct relationship between PEG loading and the effective seclusion of AChE from the hepatic asialoglycoprotein receptor clearance system. Finally, an inverse relationship is found between the extent of PEG loading and the ability of the human acetylcholinesterase to elicit specific anti-HuAChE antibodies. In conclusion, these findings suggest that for the extension of circulatory longevity, protein surface domain concealment exerted by polyethylene glycol attachment is at least as important as its effect on size enlargement and highlights the role of PEG attachment in masking interactions between biomolecules and their cognate receptors.
Cohen
Ofer
O
Department of Biochemistry, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.
Kronman
Chanoch
C
Lazar
Arie
A
Velan
Baruch
B
Shafferman
Avigdor
A
D000110:Acetylcholinesterase / Q000276:immunology* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D000906:Antibodies / Q000276:immunology; D037263:Asialoglycoprotein Receptor / Q000276:immunology; D002460:Cell Line; D006801:Humans; D051379:Mice; D008813:Mice, Inbred ICR; D009154:Mutation; D062025:Organophosphate Poisoning; D011092:Polyethylene Glycols / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000502:physiology; D011994:Recombinant Proteins / Q000276:immunology* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012794:Sialic Acids / Q000276:immunology
D000906:Antibodies; D037263:Asialoglycoprotein Receptor; D011994:Recombinant Proteins; D012794:Sialic Acids; D011092:Polyethylene Glycols; D000110:Acetylcholinesterase